ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 4, 2013, Pages 1500-1505

  Blankman, Jacqueline L ^a   Long, Jonathan Z ^a   Trauger, Sunia A ^a   Siuzdak, Gary ^a   Cravatt, Benjamin F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOPHOSPHATIDYLSERINE; TOLL LIKE RECEPTOR 2; TRIACYLGLYCEROL LIPASE;

ABHD12 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; CATARACT; CELL ACTIVATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ACTIVITY; GENE; GENE FUNCTION; GENE MUTATION; HEARING IMPAIRMENT; LIPID BRAIN LEVEL; METABOLOMICS; MICROGLIA; MOLECULAR MODEL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RETINITIS PIGMENTOSA;

ANIMALS; ATAXIA; BEHAVIOR, ANIMAL; BRAIN; CATARACT; DISEASE MODELS, ANIMAL; HUMANS; LIPID METABOLISM; LYSOPHOSPHOLIPIDS; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; MODELS, NEUROLOGICAL; MONOACYLGLYCEROL LIPASES; MUTATION; PHENOTYPE; POLYNEUROPATHIES; RETINITIS PIGMENTOSA;

MAMMALIA; MURINAE; MUS;

EID: 84872867557     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217121110     Document Type: Article

References (37)

1. Online Mendelian Inheritance in Man (2012) McKusick-Nathans Institute of Genetic Medicine (John Hopkins University, Baltimore). Available at http://omim.org. Accessed September 15, 2012.
2. Fiskerstrand T, et al. (2009) A novel Refsum-like disorder that maps to chromosome 20. Neurology 72(1):20-27.
3. Fiskerstrand T, et al. (2010) Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism. Am J Hum Genet 87(3):410-417.
4. Eisenberger T, et al. (2012) Targeted next-generation sequencing identifies a homozygous nonsense mutation in ABHD12, the gene underlying PHARC, in a family clinically diagnosed with Usher syndrome type 3. Orphanet J Rare Dis 7(1):59.
5. Blankman JL, Simon GM, Cravatt BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14(12):1347-1356.
6. Simon GM, Cravatt BF (2010) Activity-based proteomics of enzyme superfamilies: Serine hydrolases as a case study. J Biol Chem 285(15):11051-11055.
7. Pujol A, et al. (2002) Late onset neurological phenotype of the X-ALD gene inactivation in mice: A mouse model for adrenomyeloneuropathy. Hum Mol Genet 11(5):499-505.
8. Wheeler VC, et al. (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knockin mice. Hum Mol Genet 9(4):503-513.
9. Lorenzetti D, et al. (2000) Repeat instability and motor incoordination in mice with a targeted expanded CAG repeat in the Sca1 locus. Hum Mol Genet 9(5):779-785.
10. Shinzawa K, et al. (2008) Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: A model of human neurodegenerative disease. J Neurosci 28(9): 2212-2220.
11. Saghatelian A, et al. (2004) Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry 43(45):14332-14339.
12. Gross RW, Han X (2011) Lipidomics at the interface of structure and function in systems biology. Chem Biol 18(3):284-291.
13. Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G (2006) XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 78(3):779-787.
14. Makide K, Kitamura H, Sato Y, Okutani M, Aoki J (2009) Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. Prostaglandins Other Lipid Mediat 89(3- 4):135-139.
15. Bigon E, Bruni A, Mietto L, Toffano G (1980) Lysophosphatidylserine- induced release of intra-cellular amines in mice. Br J Pharmacol 69(1):11-12.
16. Martin TW, Lagunoff D (1979) Interactions of lysophospholipids and mast cells. Nature 279(5710):250-252.
17. Smith GA, Hesketh TR, Plumb RW, Metcalfe JC (1979) The exogenous lipid requirement for histamine release from rat peritoneal mast cells stimulated by concanavalin A. FEBS Lett 105(1):58-62.
18. Frasch SC, et al. (2008) NADPH oxidase-dependent generation of lysophosphatidylserine enhances clearance of activated and dying neutrophils via G2A. J Biol Chem 283(48):33736-33749.
19. Frasch SC, et al. (2011) Signaling via macrophage G2A enhances efferocytosis of dying neutrophils by augmentation of Rac activity. J Biol Chem 286(14):12108-12122.
20. Park KS, Lee HY, Kim M-K, Shin EH, Bae Y-S (2005) Lysophosphatidylserine stimulates leukemic cells but not normal leukocytes. Biochem Biophys Res Commun 333(2): 353-358.
21. Lee SY, et al. (2008) Lysophosphatidylserine stimulates chemotactic migration in U87 human glioma cells. Biochem Biophys Res Commun 374(1):147-151.
22. Park KS, et al. (2006) Lysophosphatidylserine stimulates L2071 mouse fibroblast chemotactic migration via a process involving pertussis toxin-sensitive trimeric G-proteins. Mol Pharmacol 69(3):1066-1073.
23. van der Kleij D, et al. (2002) A novel host-parasite lipid cross-talk. Schistosomal lysophosphatidylserine activates toll-like receptor 2 and affects immune polarization. J Biol Chem 277(50):48122-48129.
24. Okun E, et al. (2009) Toll-like receptors in neurodegeneration. Brain Res Brain Res Rev 59(2):278-292.
25. Kinsner A, et al. (2006) Highly purified lipoteichoic acid induced pro-inflammatory signalling in primary culture of rat microglia through Toll-like receptor 2: Selective potentiation of nitric oxide production by muramyl dipeptide. J Neurochem 99(2): 596-607.
26. Neher JJ, et al. (2011) Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death. J Immunol 186(8):4973-4983.
27. Lehnardt S, et al. (2006) A mechanism for neurodegeneration induced by group B streptococci through activation of the TLR2/MyD88 pathway in microglia. J Immunol 177(1):583-592.
28. Hoffmann O, et al. (2007) TLR2 mediates neuroinflammation and neuronal damage. J Immunol 178(10):6476-6481.
29. Sango K, et al. (1995) Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet 11(2):170-176.
30. Lu J-F, et al. (1997) A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci USA 94(17):9366-9371.
31. Benito C, et al. (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23(35):11136-11141.
32. Yiangou Y, et al. (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6(1):12.
33. Walter L, et al. (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23(4):1398-1405.
34. Sánchez AJ, García-Merino A (2012) Neuroprotective agents: Cannabinoids. Clin Immunol 142(1):57-67.
35. Schlosburg JE, et al. (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13(9):1113-1119.
36. Nomura DK, et al. (2011) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334(6057):809-813.
37. Long JZ, et al. (2011) Metabolomics annotates ABHD3 as a physiologic regulator of medium-chain phospholipids. Nat Chem Biol 7(11):763-765.